About this episode
Experts discuss the future of treatment for locally advanced head and neck squamous cell carcinoma, focusing on trial data and team coordination.
Faculty: Ravindra Uppaluri, MD, PhD Faculty: Nancy Lee, MD, FASTRO This activity reviews data from the KEYNOTE-689 and NIVOPOSTOP trials evaluating perioperative immune checkpoint inhibition in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). Experts examine trial design, efficacy outcomes, and the role of PD-L1 combined positive score (CPS) in patient selection. Drs. Uppaluri and Lee discuss how surgical, medical, and radiation oncology teams can coordinate treatment sequencing and integrate perioperative pembrolizumab into practice for patients with locally advanced HNSCC.
People in this episode
Guests: Ravindra Uppaluri, MD, PhD, Nancy Lee, MD, FASTRO
Topics covered
- head and neck cancer
- immune checkpoint inhibition
- perioperative care
- oncology
- treatment sequencing
Keywords
- HNSCC
- immune checkpoint inhibition
- KEYNOTE-689
- NIVOPOSTOP
- pembrolizumab
- treatment sequencing
- oncology
Mentioned in this episode
Organizations: KEYNOTE-689, NIVOPOSTOP, pembrolizumab, head and neck squamous cell carcinoma (HNSCC)
More episodes of CME
- Counseling Patients on Their Future with Biologics · May 14, 2026 · 1 min
- Safety in oHCM Therapy: How and When to Transition Treatment? · May 2, 2026 · 11 min
- Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines · April 30, 2026 · 12 min
- Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies · April 10, 2026 · 58 min
- Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source · April 7, 2026 · 14 min
- Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider! · March 31, 2026 · 16 min
Explore listener stats, chart rankings, contacts and more on the CME podcast page.